KLRS
What one share of Kalaris Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs.
Kalaris Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.06 |
|---|---|
| Cash and investments | $1.81 |
| Book value | $2.42 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.13 | −$18.54 | $0.26 | −$15.94 | — | −$24.53 |
| 2020 | — | −$2.59 | $0.01 | −$2.27 | — | — |
| 2021 | — | −$2.74 | $0.00 | −$1.69 | — | $3.54 |
| 2022 | — | −$2.20 | — | −$1.85 | — | $2.41 |
| 2023 | — | −$42.09 | — | −$27.51 | — | −$9.07 |
| 2024 | — | −$51.77 | — | −$15.47 | — | −$71.23 |
| 2025 | — | −$2.85 | $0.01 | −$2.53 | — | $3.44 |